In Depth Research on Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

“Cancer Growth Inhibitors Market & Clinical Pipeline Analysis” Report Highlight:

* Introduction & Classification of Cancer Growth Inhibitors
* Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
* Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
* Markets Cancer Growth Inhibitors: 48 Drugs
* Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
* HDAC Inhibitors Clinical Pipeline: 65 Drugs
* MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
* PI3k Clinical Pipeline: 89 Drugs
* Proteasome Inhibitors Clinical Pipeline: 19 Drugs
* Global Cancer Growth Inhibitors Market Future Prospects

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Cancer-Growth-Inhibitors-Market-&-Clinical-Pipeline-Analysis.php

Table of Contents

1. Introduction to Cancer Growth Inhibitors

2. Classification of Cancer Growth Inhibitors

3. Cancer Growth Inhibitors Mechanism

4. Global Cancer Growth Inhibitors Market Overview
4.1 Current Market Scenario
4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

5. Global Cancer Growth Inhibitors Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. Global Cancer Growth Inhibitors Market Future Prospects

7. Cancer Tyrosine Kinase Clinical Insight by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered

8. Marketed Cancer Tyrosine Kinase Clinical Insight

9. HDAC Inhibitors Clinical Insight by Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Registered

10. Marketed HDAC Inhibitors Clinical Insight by Company & Indication

11. MTOR Protein Inhibitors Clinical Insight by Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-III
11.8 Preregistration
11.9 Registered

12. Marketed MTOR Protein Inhibitors Clinical Insight by Company & Indication

13. PI3K Inhibitors Clinical Insight by Company, Indication & Phase
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III

14. Marketed PI3K Inhibitors Clinical Insight by Company & Indication

15. Proteasome Inhibitors Clinical Insight by Company, Indication & Phase
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-III

16. Marketed Proteasome Inhibitors Clinical Insight by Company & Indication

17. Competitive Landscape
17.1 Advaxis
17.2 Amgen
17.3 AstraZeneca
17.4 Bristol Mayer Squibb
17.5 Celldex Therapeutics
17.6 Eli Lily
17.7 GalaxoSmithKline
17.8 Genetech
17.9 ImmunoCellular Therapeutics
17.10 ImmunoGen
17.11 Merck
17.12 Novartis
17.13 Pfizer
17.14 Roche
17.15 Sanofi
17.16 Teva

Figure 1-1: Benefits of Cancer Growth Inhibitors
Figure 1-2: Functions of Cancer Growth Inhibitors
Figure 1-3: Improvement Required for Cancer Growth Inhibitor
Figure 2-1: Cancer Growth Inhibitors Classification
Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
Figure 3-1: Generalized Working of Cancer Growth Inhibitors
Figure 3-2: Mechanism of Bortezomib
Figure 3-3: Mechanism of Vismodegib
Figure 3-4: Mechanism of Everolimus
Figure 3-5: Mechanism of Bevacizumab
Figure 3-6: Mechanism of Imatinib
Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
Figure 4-5: HDAC Pipeline by Phase (%), 2015
Figure 4-6: HDAC Pipeline by Phase (Number), 2015
Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-13: PI3K Pipeline by Phase (%), 2015
Figure 4-14: PI3K Pipeline by Phase (Number), 2015
Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
Figure 17-1: Advaxis Clinical Pipeline
Figure 17-2: Celldex Therapeutics Clinical Pipeline
Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
Figure 17-4: ImmunoGen Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.